Pertuzumab

Non-Small-Cell Lung Cancer (NSCLC) Pipeline Landscape Report 2024: Comprehensive Insights About 100+ Companies and 120+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Pharmaceutical, Health, Oncology, Clinical Trials, Therapy, NSCLC, Acquisition, Neoplasm, Cancer, Non-small-cell lung cancer, Messenger, NRG1, News, Pertuzumab, Epitope, PD-1, Discovery, Antibody, HER2, Lung cancer, HER3, Immunoglobulin G, Trastuzumab, Clinical trial, Immunology, NDA, ERBB2, DNA, Pharmaceutical industry

This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape.
  • A detailed picture of the Non-Small-Cell Lung cancer (NSCLC) pipeline landscape is provided which includes the disease overview and Non-Small-Cell Lung cancer (NSCLC) treatment guidelines.
  • The assessment part of the report embraces, in depth Non-Small-Cell Lung cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small-Cell Lung cancer (NSCLC) R&D.

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Retrieved on: 
Tuesday, December 5, 2023
ISAC, Neoplasm, Immunotherapy, HER2, Breast cancer, Trastuzumab, Roche, FC, Data, City, Research, Therapy, Publication, Pharmacokinetics, Clinical trial, Society, Bolt, MBC, Poster, Oncology, Pertuzumab, Patient, Safety, Assistant professor, Vaccine

The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).

Key Points: 
  • The trial will treat patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®).
  • “Patients with HER2-positive breast cancer who progress after Enhertu have few therapeutic options,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics.
  • “BDC-1001 has a unique mechanism of action compared to available agents, mobilizing the patient’s immune system to fight cancer.
  • Title: Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 +/- pertuzumab in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan.

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
Friday, December 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

Lunit Presents Groundbreaking Study on Predicting Treatment Response by HER2 Analysis in Colorectal Cancer

Retrieved on: 
Tuesday, August 1, 2023
DNA, Circulating tumor DNA, Therapy, HER2, Marie Cassidy, Pertuzumab, Breast, IHC, ASCO, American Society of Clinical Oncology, Patient, WSI, Somatostatin receptor 2, AI, Neoplasm, Society, ORR, Medical device, Medical imaging, Trastuzumab

SEOUL, South Korea, Aug. 1, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of a groundbreaking study at the ASCO (American Society of Clinical Oncology) Breakthrough conference, to be held from August 3 to August 5 in Yokohama, Japan.

Key Points: 
  • This study showcases the potential of Lunit SCOPE HER2, an AI-powered solution designed to detect HER2 expression profile in detail, to provide valuable insights that can predict treatment response, thereby advancing personalized medicine in mCRC patients.
  • The study employed a higher HER2 cutoff (HER2 3+ higher than 50%) than the standards used in breast and gastric cancers (HER2 3+ higher than 10%).
  • "This groundbreaking study marks a significant milestone for Lunit and reinforces our commitment to advancing personalized medicine in cancer treatment," said Brandon Suh, CEO of Lunit.
  • "The findings from this study demonstrate the potential of Lunit SCOPE HER2 to provide valuable insights in predicting treatment response for HER2-positive metastatic colorectal cancer patients.

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL

Retrieved on: 
Thursday, June 15, 2023
Partnership, The, Arm, HER2, Trastuzumab, Survival, Quality of life, PCR, University Hospital Arnau de Vilanova, Rated R, Congress, The Lancet, Patient, Pertuzumab, IDF field hospital for Gazans, IBCC, Breast cancer, Medical imaging, Pharmaceutical industry

The results were obtained from analysis of HER2DX® in tumor samples from the PHERGAIN phase II clinical trial, led by MEDSIR (Spain).

Key Points: 
  • The results were obtained from analysis of HER2DX® in tumor samples from the PHERGAIN phase II clinical trial, led by MEDSIR (Spain).
  • "The results of HER2DX® in PHERGAIN are remarkable and support the strong predictive and prognostic value of the test in patients with early-stage HER2+ breast cancer.
  • Dr. Patricia Villagrasa, CEO and Co-founder of REVEAL GENOMICS® concluded, "Today's positive results for HER2DX® are a significant step forward for our company.
  • Detailed results of this study will be presented at a future medical congress and submitted for publication.

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL

Retrieved on: 
Thursday, June 15, 2023
Partnership, The, Arm, HER2, Trastuzumab, Survival, Quality of life, PCR, University Hospital Arnau de Vilanova, Rated R, Congress, The Lancet, Patient, Pertuzumab, IDF field hospital for Gazans, IBCC, Breast cancer, Medical imaging, Pharmaceutical industry

The results were obtained from analysis of HER2DX® in tumor samples from the PHERGAIN phase II clinical trial, led by MEDSIR (Spain).

Key Points: 
  • The results were obtained from analysis of HER2DX® in tumor samples from the PHERGAIN phase II clinical trial, led by MEDSIR (Spain).
  • "The results of HER2DX® in PHERGAIN are remarkable and support the strong predictive and prognostic value of the test in patients with early-stage HER2+ breast cancer.
  • Dr. Patricia Villagrasa, CEO and Co-founder of REVEAL GENOMICS® concluded, "Today's positive results for HER2DX® are a significant step forward for our company.
  • Detailed results of this study will be presented at a future medical congress and submitted for publication.

EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives

Retrieved on: 
Wednesday, May 3, 2023
Francs, National health insurance, Optimism, HER2, Trastuzumab, Survival, Clinical trial, Pertuzumab, Pharmacokinetics, Negotiation, Patent, Patient, Breast cancer, Fine chemical, EU

TAIPEI, May 3, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe.

Key Points: 
  • TAIPEI, May 3, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A in Europe.
  • In combination with the first-generation HER2-positive antibody drug Trastuzumab, Pertuzumab has a synergistic effect in the treatment of early-stage HER2-positive breast cancer and metastatic breast cancer.
  • The success of EG1206A's phase 1 clinical trial is an important milestone for EirGenix and its development of biosimilar drug products for the treatment of HER2-positive breast cancer.
  • The clinical combination of trastuzumab and pertuzumab has a synergistic effect in the treatment of early-stage HER2-positive breast cancer and metastatic breast cancer.

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Therapy, McCormick Place, Cancer, Publication, ASCO, ISAC, Patient, Pertuzumab, Annual general meeting, Poster, BMS, Society, American Society of Clinical Oncology, Safety, Nivolumab, Pharmaceutical industry

The conference is being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.

Key Points: 
  • The conference is being held at McCormick Place in Chicago, Illinois and virtually from June 2-6, 2023.
  • BDC-1001 is an investigational Immune-Stimulating Antibody Conjugate (ISAC) in development for the treatment of patients with HER2-expressing cancer.
  • The ASCO presentation will include comprehensive results from the company’s Phase 1 single-agent and combination dose-escalation trial of BDC-1001 that enrolled more than 100 patients.
  • Additionally, a copy of the poster will be available on the Publications page of the Bolt Biotherapeutics website following the conference.

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

Retrieved on: 
Wednesday, March 29, 2023
Memorial Sloan Kettering Cancer Center, PRS, Initiation, Therapy, HER2, Trastuzumab, Roche, Clinical trial, Cancer, Breast, Bristol Myers Squibb, Bolt, ISAC, Patient, Pertuzumab, MSK, Neoplasm, MPH, FC, Safety, Nivolumab, Vaccine, Pharmaceutical industry

Topline findings from this trial indicate that BDC-1001 was well tolerated at all dose levels and schedules evaluated, both as monotherapy and in combination with nivolumab.

Key Points: 
  • Topline findings from this trial indicate that BDC-1001 was well tolerated at all dose levels and schedules evaluated, both as monotherapy and in combination with nivolumab.
  • Moreover, biomarker data demonstrate that corresponding clinical and safety data are related to the ISAC mechanism.
  • These data support the selection of a RP2D and advancement to Phase 2 studies.
  • Bristol Myers Squibb, Bolt’s clinical collaborator for this study, will continue to supply nivolumab at no cost for such expansion cohorts.

REVEAL GENOMICS Presents the Latest HER2DX® Data in HER2+ Breast Cancer at SABCS 2022

Retrieved on: 
Tuesday, December 6, 2022
Technology, Medical Devices, Genetics, Clinical Trials, Stem Cells, Other Health, Biotechnology, Health, Data Management, Oncology, Biotechnology, Vall, Recurrence, Pertuzumab, TCH, Dana–Farber Cancer Institute, Chain reaction, TCHP, American Journal of Clinical Oncology, Trastuzumab emtansine, THP, Paclitaxel, Biomarker, Patient, HER2, Carboplatin, Cancer, COMPASS, Research, The New England Journal of Medicine, Breast cancer, CSO, ERBB2, Survival, Journal, University of Barcelona, Clinical trial, University, Hospital, GOM, Daphne, Machine learning, Trastuzumab, APT, Risk, Medical imaging, Pharmaceutical industry

These extraordinary results will undoubtedly be key to achieving our goal of making HER2DX available globally and reaching all patients with HER2+ breast cancer.

Key Points: 
  • These extraordinary results will undoubtedly be key to achieving our goal of making HER2DX available globally and reaching all patients with HER2+ breast cancer.
  • We are very excited about what the future holds for us as a company, adds Dr. Patricia Villagrasa-Gonzalez, Co-founder and CEO of REVEAL GENOMICS.
  • Marketed by REVEAL GENOMICS since January 2022, HER2DX is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
  • REVEAL GENOMICS and HER2DX are registered trademarks of REVEAL GENOMICS, S.L.